We’re Focused on Transforming Antibody Therapeutics With Multi-Payload Conjugate Technology

CatenaBio is developing Multi-Payload Conjugate (MPC) technology by combining two payloads with different mechanisms of action (MOAs) on a single antibody.

CatenaBio is developing Multi-Payload Conjugate (MPC) technology by combining two payloads with different mechanisms of action (MOAs) on a single antibody.

Rationale

Single-MOA payload is an enormous limitation of current antibody-drug conjugates (ADCs)

Key Advantage

We can create MPCs unobtainable by existing means

Indication

Solid tumors

Lead Assets

CATB-101

Validated antibody with two mechanistically distinct therapeutic payloads

CATB-102

Undisclosed novel MPC